Release #:812-185522-rl-1235735: BioElectronics
Post# of 7805
(Total Views: 391)
Posted On: 12/02/2019 7:22:38 AM
Release #:812-185522-rl-1235735:
BioElectronics
Investor Updates December 2, 2019
Endonovo Lawsuit Update
We are pleased to announce that on November 25, 2019, Endonovo Therapeutics Inc. filed for Voluntarily Dismissal of its lawsuit against BioElectronics Corp., without prejudice. This move follows Jurisdictional Discovery paperwork filed on November 19, 2019 by the legal counsel representing BioElectronics. BioElectronics is considering its legal options against Endonovo, while prioritizing its resources on closing deals and increasing sales.
BioElectronics management received notice in June 2019 that Endonovo Therapeutics, Inc. filed a lawsuit against BioElectronics in the United States District Court for the Central District of California. The lawsuit asserted that BioElectronics' ActiPatch® medical device infringed on Endonovo’s US Patent Nos. 7,740,574 and 7,758,490. The lawsuit requested relief that is characteristic of patent infringement lawsuits, including damages and injunctive relief.
CE Mark/ISO Certification Renewal Status Update
On Wednesday, November 25 NEMKO informed us that the lead reviewer was requesting clarification on some of the submissions in the technical file. We are preparing the necessary documentation for submission to NEMKO for further review.
There are no further updates regarding the ISO 13485 certificate, as we continue to wait for NEMKO to issue the certificate.
FDA/Allay/Sales Updates
There is no new information regarding these sections but will keep the investor community aware of any updates.
12/2/2019 7:17:21 AM
BioElectronics
Investor Updates December 2, 2019
Endonovo Lawsuit Update
We are pleased to announce that on November 25, 2019, Endonovo Therapeutics Inc. filed for Voluntarily Dismissal of its lawsuit against BioElectronics Corp., without prejudice. This move follows Jurisdictional Discovery paperwork filed on November 19, 2019 by the legal counsel representing BioElectronics. BioElectronics is considering its legal options against Endonovo, while prioritizing its resources on closing deals and increasing sales.
BioElectronics management received notice in June 2019 that Endonovo Therapeutics, Inc. filed a lawsuit against BioElectronics in the United States District Court for the Central District of California. The lawsuit asserted that BioElectronics' ActiPatch® medical device infringed on Endonovo’s US Patent Nos. 7,740,574 and 7,758,490. The lawsuit requested relief that is characteristic of patent infringement lawsuits, including damages and injunctive relief.
CE Mark/ISO Certification Renewal Status Update
On Wednesday, November 25 NEMKO informed us that the lead reviewer was requesting clarification on some of the submissions in the technical file. We are preparing the necessary documentation for submission to NEMKO for further review.
There are no further updates regarding the ISO 13485 certificate, as we continue to wait for NEMKO to issue the certificate.
FDA/Allay/Sales Updates
There is no new information regarding these sections but will keep the investor community aware of any updates.
12/2/2019 7:17:21 AM
(0)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼